156 related articles for article (PubMed ID: 1735078)
41. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
42. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Loeffler TM; Hausamen TU
J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
[TBL] [Abstract][Full Text] [Related]
43. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
45. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Wadler S; Schwartz EL; Goldman M; Lyver A; Rader M; Zimmerman M; Itri L; Weinberg V; Wiernik PH
J Clin Oncol; 1989 Dec; 7(12):1769-75. PubMed ID: 2585018
[TBL] [Abstract][Full Text] [Related]
46. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Weh HJ; Platz D; Braumann D; Buggisch P; Schmiegel WH; Drescher S; Kleeberg UR; Müllerleile U; Crone-Münzebrock W; Hoffman R
Semin Oncol; 1992 Apr; 19(2 Suppl 3):180-4. PubMed ID: 1557644
[TBL] [Abstract][Full Text] [Related]
47. A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors.
Saltz L; Kemeny N; Schwartz G; Kelsen D
Cancer; 1994 Aug; 74(3):958-61. PubMed ID: 8039124
[TBL] [Abstract][Full Text] [Related]
48. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
49. Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
Knuth A; Bernhard H; Klein O; Meyer zum Büschenfelde KH
Semin Oncol; 1992 Apr; 19(2 Suppl 3):211-4. PubMed ID: 1557650
[TBL] [Abstract][Full Text] [Related]
50. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
51. A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma.
Koo WH; Ang PT
Ann Acad Med Singap; 1996 Mar; 25(2):210-4. PubMed ID: 8799007
[TBL] [Abstract][Full Text] [Related]
52. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
[TBL] [Abstract][Full Text] [Related]
53. Chemo-biotherapy with 5-fluorouracil, leucovorin, and alpha interferon in metastatic carcinoma of the colon--a Cancer Biotherapy Research Group [CBRG] phase II study.
Soori GS; Oldham RK; Dobbs TW; Bury MJ; Church CK; DePriest C
Cancer Biother Radiopharm; 2000 Apr; 15(2):175-83. PubMed ID: 10803323
[TBL] [Abstract][Full Text] [Related]
54. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
55. Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon.
Atzpodien J; Kirchner H; Hänninen EL; Menzel T; Deckert M; Franzke A; Schomburg A; Poliwoda H
Oncology; 1994; 51(3):273-5. PubMed ID: 8196911
[TBL] [Abstract][Full Text] [Related]
56. Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
Köhne CH; Wilke H; Hiddemann W; Bokemeyer C; Lohrmann HP; Bodenstein H; Preiss J; Rauschecker H; Hill H; Kaufer C; Fischer JT; Ohl U; Urbanitz D; Balleisen L; Schmoll HJ
Oncology; 1997; 54(2):96-101. PubMed ID: 9075778
[TBL] [Abstract][Full Text] [Related]
57. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Ravaud A; Audhuy B; Gomez F; Escudier B; Lesimple T; Chevreau C; Douillard JY; Caty A; Geoffrois L; Ferrero JM; Linassier C; Drevon M; Négrier S
J Clin Oncol; 1998 Aug; 16(8):2728-32. PubMed ID: 9704724
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
59. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Yee LK; Allegra CJ; Steinberg SM; Grem JL
J Natl Cancer Inst; 1992 Dec; 84(23):1820-5. PubMed ID: 1433371
[TBL] [Abstract][Full Text] [Related]
60. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
